Study design
Cancer
ONCOLOGY, CANCER
The current single-arm, prospective phase II trial was performed at the Oncology Department of Jiangsu Cancer Hospital between March 2019 and March 2022. The study followed the Declaration of Helsinki (2000), and had approval from the Ethics Committee of Jiangsu Cancer Hospital. Each patient provided signed informed consent. The current trial was registered at the Chinese clinical trial registry (